

2026 Spring Law Update

Sheri Zapadka PharmD, RPh
Compliance Specialist
Ohio Board of Pharmacy



Pharmacy Forward: Advancing Practice for a
Healthier Tomorrow!

OPA Annual Conference & Trade Show April 9-11, 2026



Disclosure Statement

- Sheri Zapadka has no relevant financial relationship(s) with ineligible companies to disclose.

and


- None of the planners for this activity have relevant financial relationships with ineligible companies to disclose.



Learning Objectives



At the completion of this activity, the participant will be able to:

1. Review recent changes and additions to OAC 4729
 2. Explore compounding, medical spas, and IV hydration clinics
 3. Discuss investigative cases and board actions
 4. Reference board notices and links
- 

OAC 4729

RECENT CHANGES

OAC 4729:1-3-02 – EFFECTIVE 1/7/2026

ADMINISTRATION OF DANGEROUS DRUGS BY INJECTION

- Administer sub-q or IM
- Must be prescribed
 - Long-acting or extended-release forms of addiction treatment drugs
 - Long-acting or extended-release antipsychotics
 - Long-acting HIV treatment or prevention drugs
 - Hydroxyprogesterone caproate
 - Medroxyprogesterone acetate
 - Cobalamin (includes cyanocobalamin, hydroxocobalamin or other vitamin B-12 injections)
 - Antibiotics
 - Denosumab or romosozuma
 - Methotrexate for non-emergent conditions
 - Heparin, LMW Heparin, and factor Xa inhibitors

OAC 4729:1-3-02

ADMINISTRATION OF DANGEROUS DRUGS INJECTION

- Training
 - Course in drug administration
 - Basic life-support
 - Practice in accordance with a protocol
- Compliance:
 - Permission in writing for minors
 - Permission in writing for individuals unable to make informed health decisions
 - Notification of a right to privacy and/or chaperone when injections are given
 - For addiction treatment – test results prior to initial dose or any dose more than 30 days after the last
 - Observation for adverse reactions
 - Notification to prescriber within 7-days of administrations (confirmed)

OAC 4729:5-5-04 – Effective 1/15/2027

RECORD KEEPING

- Effective 1/15/2027
 - **All Ohio outpatient pharmacies** must have an electronic means of recoding positive ID.
 - Hard-copy records and manual signatures will no longer be permitted.
- **EXCEPTIONS:**
 - Compounding and the dispensing of compounded drugs
 - Ancillary services (OAC 4729:5-5-02.1)
- **Waivers:**
 - May be granted upon written request
 - Pharmacy must demonstrate undue economic hardship and that proposed systems ensure patient safety

ORC 4729.51

SELLING PURCHASING DISTRIBUTING OR DELIVERING DANGEROUS OR INVESTIGATIONAL DRUGS

If distributing investigational new drugs or products in phase 2 or phase 3 to entities in Ohio (ex. sending to an Ohio hospital participating in a clinical trial), you must be licensed as one of the following:

License Type	Description
Manufacturer of Dangerous Drugs	Manufactures the drug or product and ships into Ohio.
Wholesale Distributor of Dangerous Drugs	Owns the drug or product and ships into Ohio.
Outsourcing Facility	Compounds the drug or product and ships into Ohio.
Virtual Wholesale Distributor of Dangerous Drugs	Owns the drug or product but uses an Ohio licensed third-party logistics provider (3PL) to ship into Ohio.
Terminal Distributor of Dangerous Drugs – Pharmacy	If conducting an occasional wholesale sale of a drug or product. NOTE: Ohio law prohibits a pharmacy from engaging in wholesale sales that exceed five per cent of the total dosage units dispensed by the pharmacy during the same calendar year (see OAC 4729:5-3-09).
Terminal Distributor of Dangerous Drugs - Non-Resident Pharmacy	

IMPORTANT: Per [Board resolution](#), the licensure requirements listed above **DO NOT APPLY** to any investigational new drugs or products that are currently in a phase 1 clinical trial. Those engaged in phase 1 clinical trials that are expected to enter phase 2 are strongly encouraged

COMPOUNDING

MEDICAL SPAS

IV HYDRATION CLINICS

PRESCRIBER CLINIC AND MED SPA VIOLATIONS

Over the last year, the board has suspended over 30 clinics and medical spas due to clear and convincing evidence that the clinics pose a danger of immediate and serious harm to others.

PRESCRIBER CLINIC AND MED SPA VIOLATIONS

Purchasing from unlicensed sellers

- Facebook, social media, internet sellers, other clinics or prescriber offices, cold calls from brokers
- Verify your seller: OAC 47296:5-3-04

License Look-Up

To locate a license, start by selecting either 'INDIVIDUAL' or 'BUSINESS' from the search options provided below. Input your search criteria and then press the 'SEARCH' button. The relevant information will be displayed in a list at the bottom of the screen. For further details about the license or to obtain a printer-friendly version, click on the VIEW MORE INFO button located on the far right. To review any disciplinary history associated with the license, select 'Yes' under the Board Action? column. You can download the disciplinary document by clicking 'View' next to each document listed.

Search

INDIVIDUAL BUSINESS

Note: When searching for a license it is recommended to start by selecting the Board. Searches can be conducted by entering either the entire business name or a portion of the business name. Searches will return results that contain the business name search criteria. It is crucial that any information entered matches precisely how it's stored in the system; otherwise, the business license you're seeking might not be located. The entry of more search criteria will help to narrow down your search results.

Business Name	License Number	Doing Business As
<input type="text"/>	<input type="text"/>	<input type="text"/>
City	State	County
<input type="text"/>	<input type="text" value="---Select--"/>	<input type="text" value="--None--"/>
Board	License Type	
<input type="text" value="--None--"/>	<input type="text"/>	

SEARCH

CLEAR

PRESCRIBER CLINIC AND MED SPA VIOLATIONS

Purchasing medications marked
“for research purposes only”




store refrigerated at 2°C to 8°C (36°F to 46°F). **Research purposes only.**
Store frozen at -25°C to -15°C (-13°F to 5°F)



PRESCRIBER CLINIC AND MED SPA VIOLATIONS

Purchasing medications marked “for research purposes only”



PRESCRIBER CLINIC AND MED SPA VIOLATIONS

Insanitary preparation of medications marked “unfinished drug products” or active pharmaceutical ingredients (API)



PRESCRIBER CLINIC AND MED SPA VIOLATIONS

Purchasing non-FDA approved medications including foreign-sourced drugs or drugs not permitted for compounding






PRESCRIBER CLINIC AND MED SPA VIOLATIONS

Purchasing non-FDA approved medications including foreign-sourced drugs or drugs not permitted for compounding

PRESCRIBER CLINIC AND MED SPA VIOLATIONS

Purchasing non-FDA approved medications including foreign-sourced drugs or drugs not permitted for compounding



Peptides

- ORC 4729.01: Dangerous drug" means any of the following:
 - Any drug intended for administration by **injection** into the human body other than through a natural orifice of the human body
 - Dangerous drug = Rx Only
- FDA Drug Compounding:
 - USP/NF monograph
 - Component of an FDA approved product
 - Appear on FDA 503a/b bulk list

Peptides

Peptides:

- 2-50 amino acids
- Promoted for regulating hormones, boosting immunity, repairing tissue, etc.
- Demand has outpaced regulation.
- Research on many peptides is ongoing, but FDA approvals for human indications are lacking
- Many peptides do not meet the FDA requirements for compounding, and are therefore unapproved drugs and not eligible for compounding (See bulk drug category lists)
 - Category II FDA Bulk List = poses significant safety concerns
 - Examples: BP-157, CJC-1295, Ipamorelin, thymosin alpha-1, GHK-Copper
- Availability does not imply legality
- Clinical demand is not a substitute for regulatory approval

Peptides

Peptides:

- Research Only Peptides – Not For Human Consumption
- Peptides sold as research chemicals
 - May be legal to manufacturer and sell for legitimate laboratory research
 - Introduces an unapproved drug for human use to the market, esp. if claims are made on the website re. benefits of the injectable drugs.
- Disclaimers/consent forms from vendors do not protect prescriber from federal and state laws
- Framework of care holds licensed professionals to higher standards than patient choice

Peptides

Peptides:

- Do not rely on “the norm”
- Do not rely on vendor assurances
- Research disclaimers do not authorize treatment
- Regulatory classification is paramount
- How is the peptide manufactured, distributed, or used?

PRESCRIBER CLINIC AND MED SPA VIOLATIONS


Failure to comply with compounding standards:

Concerns:

- Are qualified individuals making appropriate diagnosis?
- Are IVs prepared in a sterile manner consistent with state law?

Compounding:

- Preparation of IV cocktails is compounding
- Locations that compound must be licensed by OBP
 - RP must be onsite a sufficient amount of time
- Locations must follow prescriber compounding rules (OAC 4729:7-3)




PRESCRIBER CLINIC AND MED SPA VIOLATIONS

Failure to comply with compounding standards:

Compounding

- Usually, the immediate use rule is followed: OAC 4729:7-3-04
- Repackaging syringes for take-home requires compliance with USP 797 and OAC 4729:7-3-04 – not immediate use rules!
- Reconstitution **NOT** according to manufacturer's labeling requires compliance with USP 797 and OAC 4729:7-3-04
- Compounding can be delegated to a nurse, but the prescriber is required to verify the compounded final product before administration, or the prescriber must be physically on-site during administration
- Paramedics may **NOT** independently verify a compounded medication prior to administration
- Drugs **must** be purchased from an OBP licensed location – verified annually



PRESCRIBER CLINIC AND MED SPA VIOLATIONS

Failure to secure controlled substances

- OAC 4729:5-19-03 prohibits unlicensed people from having controlled substances (both patient specific and inventory) including testosterone
- Unlicensed people: medical assistants, office assistants, landlords, maintenance personnel, aestheticians, etc.

PRESCRIBER CLINIC AND MED SPA VIOLATIONS

Inadequate record keeping

- Temperature monitoring – daily even if the clinic is closed (OAC 4729:5-19-03)
- Inventory records – drugs received, disposed, administered (OAC 4729:5-19-04)

PRESCRIBER CLINIC AND MED SPA VIOLATIONS

Patient-specific drugs used as office stock

- Patient specific drugs dispensed by a pharmacy are the property of the patient – **Do Not** administer to other persons
- Drugs cannot be dispensed in the name of the clinic or clinic employee to be used on multiple patients
- Drugs cannot be delivered patient specific to the clinic unless delivery to the patient would result in a danger to the public or patient without increased involvement by a healthcare professional

PRESCRIBER CLINIC AND MED SPA VIOLATIONS

Labeling of multiple dose vials

- Upon the initial puncture of a multiple dose drug vial, it must be labeled with a BUD of 28-days (or per manufacturer).

PRESCRIBER CLINIC AND MED SPA VIOLATIONS

Expired/adulterated drugs in active drug stock

- Expired/adulterated drugs must be removed from inventory to prevent administration to patients
- Adulterated/expired drugs must be stored in a separate and secure area apart from the storage of drugs used for patient care

PRESCRIBER CLINIC AND MED SPA VIOLATIONS

Reminders:

1. Neurotoxin reconstitution is not considered compounding if the reconstitution follows manufacturer labeling
2. If reconstitution does not follow manufacturer labeling, it is considered compounding
3. The BUD for all neurotoxins is determined by manufacturer labeling. If no time frame exists, the drug must be used within 6 hours of preparation
4. If product labeling says “should” the board considers that time frame as a requirement
5. Neurotoxins administered after the timeframe listed on the manufacturer labeling is considered a violation of board rules

INVESTIGATIVE CASES AND BOARD ACTIONS

Veterinary Practice

- DVM was not actively practicing veterinary medicine
- DVM maintained a TDDD at a personal residence
- Controlled substances were ordered
- Attempts to inspect were refused
- Terminal distributor license was permanently revoked

Medical Spa

- Inspection found a medical spa in possession of illegal drugs.
- Drugs were purchased from illegitimate entities who were not licensed wholesale drug distributors/manufacturers.
- 413 drugs found:
 - Tirzepatide labeled by the spa – drug labeled in foreign language as “Beauty Peptide”
 - Tvgoura – labeled as tirzepatide by the med spa.
 - Drugs with self-made label “S007” purported semaglutide
 - Drugs with self-made label “R001” purported Retatrutide
 - Vials labeled “S10 – for research use only”
 - ... and others

Medical Spa

- Illegal purchases from unlicensed entities
 - Drugs prescribed for employees and used on patients (B12, D3)
 - Patient specific drugs shipped to the clinic that did not present a danger to the patient or public
 - No refrigerator temperature monitoring
 - Adulterated drug stock
 - Record keeping violations
 - Clinic compounded and personally furnished drugs not compliant with USP
-
- TDDD was permanently revoked
 - Monetary Penalty: \$300,000

Compounding Pharmacy

- Pharmacy distributed compounded dangerous drugs to Ohio patients which were in violation of the FD&C Act and could not be compounded
- Monetary Penalty: \$5,000
- Written reprimand

Outpatient Pharmacy

- Failure to conduct annual controlled substance inventories
- Vaccine administration violations (training, protocols).
- Numerous record keeping violations
- Fine \$5000
- Written Reprimand on the pharmacy and RP
- RP to obtain 6 hours of CE

Pharmacy Technician

- Investigated for theft of controlled substances
- License summarily suspended
- Technician voluntarily surrendered their license
- May not reapply until they show the board proof they are no longer addicted to drugs/alcohol or otherwise physically or mentally impaired and unfit to practice pharmacy

BOARD COMMUNICATIONS

Free Fentanyl and Xylazine Test Strips

- No cost fentanyl test strips are available to all Ohio terminal distributors (e.g., pharmacies, clinics, hospitals, EMS, etc.)
- Up to 2 boxes of fentanyl test strips per order
- 1 box of xylazine test strips
 - While supplies last
- Educational Handouts (100/pack)
- <https://www.surveymonkey.com/r/FTSORDER>

Electronic Registered mail

- Official electronic registered mail from the board will sometimes have a banner across the top stating:

Registered Mail | Certified Delivery

 REGISTERED EMAIL™ | CERTIFIED DELIVERY

This is a Registered Email™ message from Jennifer.Nelson@pharmacy.ohio.gov

Good Afternoon,

The State of Ohio Board of Pharmacy (Board) is contacting you regarding your scheduled June 3, 2024, probation appearance. The June Board Meeting will be held at the offices of the **State Board of Pharmacy, 77 South High Street, Columbus, Ohio 43215-6126**; however, you will have the option of participating in your Probation Appearance in-person or remotely.

ABOUT

VERIFY A
LICENSE

PUBLICATIONS

LICENSING
& CE

LAWS &
RULES

COMPLIANCE &
ENFORCEMENT

Protecting
Ohio Since
- 1884 -



Board of
Pharmacy

Ohio Automated Rx Reporting System



FILE A
COMPLAINT



SEARCH FOR
ACCESSIBLE SERVICES

WELCOME TO THE OHIO BOARD OF PHARMACY

Thank you for visiting our website. The Ohio Board of Pharmacy is the single state agency in Ohio responsible for administering and enforcing laws governing the practice of pharmacy and the legal distribution of drugs. Here you'll find information and resources to assist healthcare professionals, law enforcement, and the public in understanding more about Ohio's drug laws and the practice of pharmacy.

-- Steven W. Schierholt, Esq., Executive Director



> [CLICK HERE TO SUBSCRIBE TO UPDATES!](#)

> [CLICK HERE FOR MEETING DATES!](#)

RECENT UPDATES

- > Rules for Stakeholder Comment (**Comments Due 2.7.2025**)
- > 2025-01-21 Reminder OARRS Now Alerts Healthcare Providers About I
- > Ohio Public High School Approved Pharmacy Technician Training Pro
- > 202412 - December 9, 2024 Probation Committee Meeting Minutes

 [FOLLOW @OHIORXBOARD](#)

2026 Law reviews

2026 Law Review Topics:

- Remote dispensing pharmacies
- Electronic positive identification systems
- Administration of injections by pharmacists
- Updates to state and federal laws and rules

2026 Law Review Dates:

- February 20, 2026 - Friday, 1:30pm - 2:30pm (Registration closes February 18th)
- June 26, 2026 - Friday, 1:30 - 2:30pm (Registration closes June 22nd)
- September 25, 2026 - Friday, 1:30pm - 2:30pm (Registration closes September 23rd)
- December 18, 2026 - Friday, 1:30pm - 2:30pm (Registration closes December 16th)

2026 Law reviews

Prescriber Clinics/Med Spas topics:

- Top ten violations seen in inspections
- Appropriate drug procurement
- How to identify illegitimate drug products
- Prescriber clinic inspection guide and resources

- **Prescriber Clinics/Med Spas:**
- April 24, 2026 - Friday, 1:30pm - 2:30pm (Registration closes April 22nd)
- August 21, 2026 - Friday, 1:30pm - 2:30pm (Registration closes August 19th)
- November 20, 2026 - Friday, 1:30pm - 2:30pm (Registration closes November 18th)

2026 Law reviews

2026 Responsible Person 101 Topics:

- Duties and responsibilities of a responsible person
- General requirements of a terminal distributor of dangerous drugs
- An overview of resources available to a responsible person
- Responsible person requirements

2026 Responsible Person 101 Presentations:

- March 13, 2026 - Friday, 1:30pm - 2:30pm (Registration closes March 11th)
- April 10, 2026 - Friday, 1:30pm - 2:30pm (Registration closes April 8th)
- May 8, 2026 - Friday, 1:30pm - 2:30pm (Registration closes May 6th)
- July 17, 2026 - Friday, 1:30pm - 2:30pm (Registration closes July 15th)
- August 7, 2026 - Friday, 1:30pm - 2:30pm (Registration closes August 5th)
- October 9, 2026 - Friday, 1:30pm - 2:30pm (Registration closes October 7th)
- December 4, 2026 - Friday, 1:30pm - 2:30pm (Registration closes December 2nd)

VERIFY MESSAGES:

Most Recent 2 Oldest

- > 2026-01-15 e-News January 2026
- > 2026-01-09 Webinar OARRS Transition to ASAP 5.0 and Technical Updates
- > 1-5-2026 - Registered Pharmacy Tech Renewal and CE Requirements
- > 1-5-2026 Registered Pharmacy Tech Renewal - No CE Required
- > 2025-12-19 Attention Pharmacy Technicians - New Ohio Board of Pharmacy Job Posting
- > 2025-12-16 Consumer Retailer Notice Kratom-Related Products Now Illegal in Ohio - Updated 12-16-2025
- > 2025-12-15 Ohio Automated Rx Reporting System E-Newsletter - Winter 2025
- > 2025-12-12 Consumer and Retailer Notice - Kratom-Related Products Now Illegal in Ohio
- > 2025-12-11 e-News December 2025
- > 2025-12-11 - Registered Pharmacy Tech Renewal and CE Requirements
- > 2025-12-11 Registered Pharmacy Tech Renewal - No CE Required

Substance Abuse and Mental Health Resources

- [Substance Abuse and Mental Health Services Administration \(SAMHSA\) national helpline](#). 1-800-662-HELP (4357) or 1-800-487-4889 (TDD — for hearing impaired).
 - Suicide prevention lifeline
 - Treatment services locator
 - National Helpline
- Ohio Department of Mental Health and Addiction Services- 1-877-275-6364.



References

- <https://www.pharmacy.ohio.gov/documents/pubs/messages/2026-01-15%20e-news%20january%202026.pdf>
- <https://www.pharmacy.ohio.gov/documents/pubs/special/ivtherapy/joint%20Regulatory%20statement%20on%20the%20operation%20of%20retail%20iv%20therapy%20clinics%20in%20ohio.pdf>
- <https://www.pharmacy.ohio.gov/documents/pubs/special/ivtherapy/ten%20common%20prescriber%20clinic%20and%20medical%20spa%20violations.pdf>
- <https://www.pharmacy.ohio.gov/documents/licensing/ce/rplaw/2026%20law%20review%20communication.pdf>
- <https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>



Need More Information?

Sheri Zapadka PharmD, RPh
Compliance Specialist
Ohio Board of Pharmacy
contact@pharmacy.ohio.gov



Pharmacy Forward: Advancing Practice for a
Healthier Tomorrow!

OPA Annual Conference & Trade Show April 9-11, 2026

